Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 wild-type |
| Therapy | Mirdametinib + Sapanisertib |
| Indication/Tumor Type | colorectal cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 wild-type | colorectal cancer | predicted - sensitive | Mirdametinib + Sapanisertib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Sapanisertib (MLN0128) and Gomekli (mirdametinib) synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063). | 26272063 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26272063) | MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. | Full reference... |